openPR Logo
Press release

Global Orphan Drugs Market Revenue, Opportunity, Segment and Key Trends 2018-2024

04-16-2019 09:02 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Infinium Global Research

/ PR Agency: Infinium Global Research
Orphan Drugs Market

Orphan Drugs Market

Our latest research report entitled Orphan Drugs Market (by disease type (oncology, gastrointestinal, pulmonary, infectious diseases), product types (biologic and non-biologic), distribution channel (hospital pharmacies, specialty pharmacies, and retail pharmacies)) provides complete and deep insights into the market dynamics and growth of Orphan Drugs. Latest information on market risks, industry chain structure Orphan Drugs cost structure and opportunities are offered in this report. The past, present and forecast market information will lead to investment feasibility by studying the essential Orphan Drugs growth factors.

The forecast Orphan Drugs Market information is based on the present market situation, growth opportunities, development factors, and opinion of the industry experts. An in-depth analysis of the company profiles, Orphan Drugs on a global and regional level and applications is conducted. The analysis of downstream buyers, sales channel, raw materials, and industry verticals is offered in this report. According to the report the global orphan drugs market is projected to grow at a CAGR of 6.5% over the forecast period of 2018-2024.

For More Details Get Free Few Sample Pages of this Premium Report: - https://www.infiniumglobalresearch.com/reports/sample-request/1619

Growing Demand of Medicines for Rare Disease Treatment to Promote the Growth of Orphan Drug Market

Economic incentives to encourage drug companies to develop and market medicines for rare disease treatment is the key driving factor in the orphan drug market. The rising occurrence of rare cancer cases, availability of orphan drugs at the hospital pharmacy and increasing hospitalization treatment for rare diseases are expected to enhance the growth of orphan drug market over the forecast period. On the other hand, the cost associated with production and R&D is more as compared with other drugs that may be hampering the market growth. Moreover, the rising awareness of the rare disease among the population and increasing investments in R&D is projected to create several opportunities in upcoming years.

North America Dominates the Market of Orphan Drugs

North America dominates the market of orphan drugs owing to its highly developed healthcare infrastructure and favorable government regulations. In North America, the U.S. holds the largest market share in this market due to economic incentives and rising awareness about the orphan drug. Moreover, the increasing investments to treat and diagnose the rare disease also to facilitate the growth in the orphan’s drug market.

New Treatments for Rare Cancers Getting Quick Approval Under ‘Orphan Drug’ Process

In August 2018, The FDA is approving drugs for rare cancers at a record pace. Most people with these diseases are happy with the news, but there are concerns about high prices. When Ann Graham was diagnosed at age 43 with osteosarcoma, a rare bone cancer that typically occurs in children and young adults, all she really heard was “cancer,” not the “rare” part. Historically, patients with rare cancers have had few effective treatment options. Many rare cancers still have no treatment options at all.

Tetra Submits Orphan Drug Applications for Cannabinoid-Based Treatment

In August 2018, Tetra Bio-Pharma has submitted multiple orphan drug applications to the FDA for cannabinoid treatment of rare cancers and ocular diseases, the company announced in a release. An orphan drug designation would allow for fast track approvals, tax credits on clinical research and reduced registration fees, the release said. Managing rare forms of cancer presents a huge challenge for physicians,” Tetra Bio-Pharma interim CEO and chief scientific officer Guy Chamberland, MSc, Ph.D., said. “Our R&D team has submitted numerous orphan drug designation applications to the FDA over the past 6 months, which not only holds promise to improve patient care but lines up with our corporate strategy to develop and commercialize cannabinoid prescription drug products for both rare cancers and ocular diseases in the United States.”

Browse Detailed TOC, Description, and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-orphan-drugs-market

Orphan Drug Designation Granted to Bietti's Crystalline Dystrophy Gene Therapy

In August 2018, Reflection Biotechnologies Limited’s AAV-based gene therapy, the RBIO-101 program (AAV.CYP4V2), was granted an orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of Bietti's crystalline dystrophy (BCD), a rare retinal degeneration. "Receiving orphan drug designation from the FDA is a milestone,” said Richard R. Yang, founder, and CEO of ReflectionBio, in a recent statement. “This brings hope to BCD patients and their families because BCD is a devastating blinding disease for which, currently, there is no approved treatment. BCD is estimated to affect more than 100,000 patients worldwide. As the next step, we plan to advance BCD gene therapy into a human clinical trial.”

Infinium Global Research and Consulting Solutions is started with a single motto of being a business partner of the first choice. We at Infinium work on the strengths of our clients to ensure we help them consolidate their market position. We firmly believe in the fact that ‘if you are able to develop newer opportunities then you find there is no dearth of opportunities for you. With our strategic research approaches and deep dive in the market segments, we try to find out new opportunities that our clients can encash with their existing resources. Our experts with over 100 years of cumulative experience in research offer the best in the industry services to our clients to ensure that they achieve their business goals.

Infinium Global Research
Office No. 04, 06, Ganadhish Empire,
Rahatani Corner, Pune, MH 411027
Email: info@infiniumglobalresearch.com
Website: www.infiniumglobalresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Orphan Drugs Market Revenue, Opportunity, Segment and Key Trends 2018-2024 here

News-ID: 1704528 • Views: 176

More Releases from Infinium Global Research

Genome Engineering Market: Global Industry Analysis, Trends, Market Size and For …
Our latest research report entitled Genome Engineering Market (by technology (clustered regularly interspaced short palindromic repeats, and other), application (cell line engineering, animal genetic engineering, and other) and end-user (biotechnology & pharmaceutical companies, academic & government research institutes and others)) provides complete and deep insights into the market dynamics and growth of Genome Engineering. Latest information on market risks, industry chain structure Genome Engineering cost structure and opportunities are offered
Computed Tomography Market 2018 : Global Industry Growth, Opportunities, Consump …
Our latest research report entitled Computed Tomography Market (by application (cardiovascular, oncology, diagnostics, neurology, and spinal application), types (low slice, medium slice, and high slice), end- user (diagnostic services, hospitals and clinics)) provides complete and deep insights into the market dynamics and growth of Computed Tomography. Latest information on market risks, industry chain structure Computed Tomography cost structure and opportunities are offered in this report. The past, present and forecast
Global Protein Ingredients Market – Invention Analysis, Size, Share, Evolution …
Our latest research report entitled Protein Ingredients Market (by source (animal source and plant source), application (food & beverage, cosmetics & personal care, infant formulations animal feed and pharmaceuticals)) provides complete and deep insights into the market dynamics and growth of Protein Ingredients. Latest information on market risks, industry chain structure Protein Ingredients cost structure and opportunities are offered in this report. The past, present and forecast market information will
Global Hospital Beds Market 2018 Industry Demand, Segment, Statistics Report 202 …
Our latest research report entitled Hospital Beds Market (by usage (general beds, pediatric beds, pressure relief beds, bariatric beds and birthing beds), types (electric beds, manual beds, semi-electric beds), treatment (acute care bed, long term care beds)) provides complete and deep insights into the market dynamics and growth of Hospital Beds. Latest information on market risks, industry chain structure Hospital Beds cost structure and opportunities are offered in this report.

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning